tbuckley/cabot-search huggingface dataset:
Bright Light Therapy as Add-On to Inpatient Treatment in Youth With Moderate to Severe Depression
Authors: Tanja Legenbauer, Inken Kirschbaum-Lesch, Carina Jörke, Michael Kölch, Olaf Reis, Christoph Berger, Alexander Dück, Michael Schulte-Markwort, Inga Becker-Hebly, Stefanie Bienioschek, Jennifer Schroth, Christian Ruckes, Oliver Deuster, Martin Holtmann
Journal: JAMA Psychiatry (2024)

Importance Major depressive disorder is one of the most common mental disorders among adolescents, entailing severe, long-term psychosocial impairment and a high risk of chronicity. In view of the large number of patients requiring treatment, along with insufficient treatment responses with small effect sizes, innovative adjunctive treatment strategies are urgently needed. Objective To investigate whether the effect of adolescent psychiatric inpatient treatment as usual for major depressive disorder can be enhanced by simultaneous use of morning bright light therapy. Design, Setting, and Participants This was a double-blind, placebo-controlled randomized parallel-group trial with enrollment between March 2018 and November 2020 and follow-up completed in May 2021. The study took place among inpatients at 4 university hospitals for child and adolescent psychiatry across Germany. Of 248 eligible youth aged 12 to 18 years fulfilling ICD-10 criteria for major depressive disorder, 227 were randomized to bright light therapy (n = 116) or placebo red light (n = 111); 151 participants completed the study. Interventions Up to 20 sessions of either morning bright light therapy with an intensity of 10 000 lux or placebo red light (100 lux) in addition to multimodal inpatient treatment as usual over 4 weeks. Main Outcomes and Measures The primary outcome was the change in Beck Depression Inventory-II (BDI-II) score from baseline to posttreatment in the intention-to-treat sample. Results Among the 224 patients included in the intention-to-treat analyses (192 girls and 32 boys; mean [SD] age, 15.5 [1.4] years), the mean (SD) BDI-II score at baseline was 37.3 (8.7). BDI-II scores were significantly reduced after 4 weeks (postassessment) by a mean of −7.5 (95% CI, −9.0 to −6.0; Hedges g = 0.71). Bright light therapy had no impact on this change (no significant group × time effect). Loss to follow-up was 31% (n = 69) at 16 weeks and 49% (n = 110) at 28 weeks. There were 10 serious adverse events throughout the whole trial, which were not considered related to study treatment. Conclusions and Relevance The findings in this study did not indicate superiority of bright light therapy over placebo red light therapy in a large sample of adolescent inpatients with moderate or severe major depressive disorder. Both groups benefited equally from treatment as usual, showing relevant symptom reduction. Trial Registration German Clinical Trials Register: DRKS00013188
What to Expect…When You Are Having Surgery
Authors: Laleh G. Melstrom, Kelly Mahuron, Virginia Sun
Journal: JAMA Surgery (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Consent and Identifiability for Patient Images in Research, Education, and Image-Based Artificial Intelligence
Authors: Trina Salvador, Lilly Gu, Jennifer L. Hay, Nicholas R. Kurtansky, Ruth Masterson-Creber, Allan C. Halpern, Veronica Rotemberg
Journal: JAMA Dermatology (2024)

This survey study reports the perspectives and preferences of US adults regarding use of photographs of their skin in medical research, education, and development of image-based artificial intelligence (AI).
Adjuvant Immunotherapy in Stage II Melanoma—Further Risk Stratification is Needed
Authors: Hannah Rashdan, Adewole S. Adamson, Yevgeniy R. Semenov
Journal: JAMA Dermatology (2024)

This Viewpoint reviews the evidence for immune checkpoint inhibitor use in the adjuvant setting, discusses the individual and societal risks, benefits, and costs associated with immune checkpoint inhibitors, and highlights the need for more targeted patient selection approaches.
Standardizing Resident Assessment and Competency—Milestones Matter
Authors: Amanda C. Filiberto, Amalia Cochran
Journal: JAMA Surgery (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Modular vector assembly enables rapid assessment of emerging CRISPR technologies
Authors: Abby V. McGee, Yanjing V. Liu, Audrey L. Griffith, Zsofia M. Szegletes, Bronte Wen, Carolyn Kraus, Nathan W. Miller, Ryan J. Steger, Berta Escude Velasco, Justin A. Bosch, Jonathan D. Zirin, Raghuvir Viswanatha, Erik J. Sontheimer, Amy Goodale, Matthew A. Greene, Thomas M. Green, John G. Doench
Journal: Cell Genomics (2024)

The diversity of CRISPR systems, coupled with scientific ingenuity, has led to an explosion of applications; however, to test newly described innovations in their model systems, researchers typically embark on cumbersome, one-off cloning projects to generate custom reagents that are optimized for their biological questions. Here, we leverage Golden Gate cloning to create the Fragmid toolkit, a modular set of CRISPR cassettes and delivery technologies, along with a web portal, resulting in a combinatorial platform that enables scalable vector assembly within days. We further demonstrate that multiple CRISPR technologies can be assessed in parallel in a pooled screening format using this resource, enabling the rapid optimization of both novel technologies and cellular models. These results establish Fragmid as a robust system for the rapid design of CRISPR vectors, and we anticipate that this assembly approach will be broadly useful for systematic development, comparison, and dissemination of CRISPR technologies.
Achievement of therapeutic antibiotic exposures using Bayesian dosing software in critically unwell children and adults with sepsis
Authors: Ming G Chai, Quyen Tu, Menino O Cotta, Michelle J Bauer, Ross Balch, Charles Okafor, Tracy Comans, Peter Kruger, Jason Meyer, Kiran Shekar, Kara Brady, Cheryl Fourie, Natalie Sharp, Luminita Vlad, David Whiley, Jacobus P J Ungerer, Brett C Mcwhinney, Andras Farkas, David L Paterson, Julia E Clark, Krispin Hajkowicz, Sainath Raman, Seweryn Bialasiewicz, Jeffrey Lipman, Brian M Forde, Patrick N A Harris, Luregn J Schlapbach, Lachlan Coin, Jason A Roberts, Adam D Irwin
Journal: Intensive Care Medicine (2024)

Early recognition and effective treatment of sepsis improves outcomes in critically ill patients. However, antibiotic exposures are frequently suboptimal in the intensive care unit (ICU) setting. We describe the feasibility of the Bayesian dosing software Individually Designed Optimum Dosing Strategies (ID-ODS™), to reduce time to effective antibiotic exposure in children and adults with sepsis in ICU. A multi-centre prospective, non-randomised interventional trial in three adult ICUs and one paediatric ICU. In a pre-intervention Phase 1, we measured the time to target antibiotic exposure in participants. In Phase 2, antibiotic dosing recommendations were made using ID-ODS™, and time to target antibiotic concentrations were compared to patients in Phase 1 (a pre–post-design). 175 antibiotic courses (Phase 1 = 123, Phase 2 = 52) were analysed from 156 participants. Across all patients, there was no difference in the time to achieve target exposures (8.7 h vs 14.3 h in Phase 1 and Phase 2, respectively, p = 0.45). Sixty-one courses in 54 participants failed to achieve target exposures within 24 h of antibiotic commencement (n = 36 in Phase 1, n = 18 in Phase 2). In these participants, ID-ODS™ was associated with a reduction in time to target antibiotic exposure (96 vs 36.4 h in Phase 1 and Phase 2, respectively, p < 0.01). These patients were less likely to exhibit subtherapeutic antibiotic exposures at 96 h (hazard ratio (HR) 0.02, 95% confidence interval (CI) 0.01–0.05, p < 0.01). There was no difference observed in in-hospital mortality. Dosing software may reduce the time to achieve target antibiotic exposures. It should be evaluated further in trials to establish its impact on clinical outcomes.
Low-Dose Morphine Does Not Cause Sleepiness in COPD: A Secondary Analysis of a Randomized Trial
Authors: Thomas J Altree, Barbara Toson, Kelly A Loffler, Magnus Ekström, David C Currow, Danny J. Eckert
Journal: American Journal of Respiratory and Critical Care Medicine (2024)

Regular, low-dose, sustained-release morphine is frequently prescribed for persistent breathlessness in chronic obstructive pulmonary disease (COPD). However, effects on daytime sleepiness, perceived sleep quality, and daytime function have not been rigorously investigated.
Small Molecule Allosteric Inhibitor of HIPK2 as a Novel Therapy against Kidney Fibrosis
Authors: Kyung Lee, Robert Drakas, John C. He
Journal: Journal of the American Society of Nephrology (2024)

1Icahn School of Medicine at Mount Sinai, New York, New York 2Rila Therapeutics Inc, South San Francisco, California 3ShangPharma Innovations Inc, South San Francisco, California Correspondence: Dr. John C. He or Dr. Kyung Lee, email: [email protected] or [email protected]
The prevalence of cardiovascular disease risk factors among adults living in extreme poverty
Authors: Pascal Geldsetzer, Rebecca L Tisdale, Lisa Stehr, Felix Michalik, Julia Lemp, Krishna K Aryal, Albertino Damasceno, Corine Houehanou, Jutta Mari Adelin Jørgensen, Nuno Lunet, Mary Mayige, Sahar Saeedi Moghaddam, Kibachio Joseph Mwangi, Christian Bommer, Maja-Emilia Marcus, Michaela Theilmann, Cara Ebert, Rifat Atun, Justine Ina Davies, David Flood, Jennifer Manne-Goehler, Jacqueline Seiglie, Till Bärnighausen, Sebastian Vollmer
Journal: Nature Human Behaviour (2024)
Author Correction: Using BCG vaccination to protect against COVID-19: when reality fails to meet expectation
Authors: Laure F Pittet, Christie C A Noble, Nicole L Messina, Nigel Curtis
Journal: Nature reviews. Immunology (2024)

The originally published article contained several errors that have now been corrected.One trial of BCG vaccination reported a large beneficial effect, and a sentence describing the trials has been changed to reflect this; "small" has been removed from the sentence "three reported a beneficial effect on BCG vaccination."A description of one trial had not included the number of case participants and this has been amended to now read "with COVID-19 occurring in 1 of the 96 participants in the BCG group compared with 6 of the 48 in the control group."In the "What have we learnt?"section, two of the original references were mixed up and have now been corrected: "…the definition of the primary outcome in only one of these" now cites reference 12, and "In the other two trials…" now cites references 10 and 13.The authors apologise for these errors, which have now been corrected in the HTML and PDF versions of the article.
Characterization of research trends and prospects on hepatic echinococcosis over the past forty years: a bibliometric analysis
Authors: Tianen Li, Wei Su, Zhiqiang Wang, Xiao Wang, Xiaoguang Ma, Yigeng Cao, Rui Zhao
Journal: International Journal of Surgery (2024)

Background: The distribution of hepatic echinococcosis (HE) is extensive, significantly impacting public health and economic development. Therefore, analyzing global collaboration networks and tracking developmental trends over the past four decades are crucial. This study aimed to demonstrate collaboration in the field of HE and explore key topics and future directions. Materials and Methods: Bibliometric analyses were conducted using CiteSpace, Bibliometrix package of R, and VOSviewer software on HE-related studies from the Web of Science Core Collection published before August 1, 2023. Results: This study identified 2,605 records published in 196 journals by 9,860 authors from 2,607 institutes in 90 countries. Publications significantly notably increased in 2021. Developing countries like Turkey and China made notable contributions, while developed countries like the USA had higher average citation rates. The largest nodes in every cluster of the collaboration network were Hacettepe University, Tehran University, Xinjiang Medical University, Salford University, and the University of Pavia, and the top-producing authors were Wen H, Vuitton DA, Gottstein B, and Craig PS. Keyword co-occurrence analysis suggested that surgical techniques and novel drugs targeting combined immune checkpoints are the main therapeutic approaches in the future. Conclusion: Although developing countries had significantly contributed to publications on HE, the citation rate for individual articles from developed countries was significantly higher. Additionally, advancements in surgical techniques and novel drugs targeting combined immune checkpoints may emerge as the next research focus and developmental direction.
Incidence and risk factors of breast cancer-related lymphedema in Korea: a nationwide retrospective cohort study
Authors: Ha Rim Ahn, Hyeong Eun Jeong, Choyun Jeong, Sang Yull Kang, Sung Hoo Jung, Hyun Jo Youn, Jong Seung Kim
Journal: International Journal of Surgery (2024)

Background: Breast cancer-related lymphedema (BCRL) is a secondary lymphedema that occurs after breast cancer related treatments. BCRL develops from damage or dysfunction of the normally functioning lymphatic system due to surgery, radiation therapy and rarely due to cancer recurrence. This nationwide, retrospective study was aimed at investigating the incidence and risk factors of BCRL using the database of the Korean National Health Insurance Service (NHIS). Methods: Patients with newly diagnosed breast cancer who underwent breast surgery from January 1, 2017 to December 31, 2020, were recruited. The incidence was compared by four groups according to the operation type of breast cancer (breast conserving surgery (BCS) with sentinel lymph node biopsy (S), BCS with axillary lymph node dissection (A), total mastectomy (TM) with S, modified radical mastectomy(MRM)). The incidence rates of lymphedema were calculated by the number of incident events by the total follow-up period. Cox proportional hazard regression was used to calculate the risk of incidence of lymphedema based on a patients’ characteristics, breast cancer treatment and comorbidities. Results: The final cohort of operation subjects that satisfied the inclusion criteria was 34,676. BCRL occurred in 4,242 patients (12.2%), and the median follow-up period was 695.4 days. The BCRL was diagnosed in the BCS with S (8.0%), BCS with A (23.5%), TM with S (10.7%), MRM (28.5%) with an incidence of 40.8, 132.2, 55.8 and 171.8 per 1,000 person-years, respectively. Young age, obesity, chemotherapy, radiotherapy, residence in metropolitan areas and hyperlipidemia were identified as risk factors. Conclusion: In Korea, the incidence of BCRL was found to be 12.2%, with the highest risk observed among patients who underwent MRM. Therefore, surgical oncologists should meticulously assess the appropriate surgical approach and consider providing education to patients with risk factors for BCRL, aiming to ensure effective prevention strategies.
A commentary on ‘Impact of lymphadenectomy extent on immunotherapy efficacy in postresectional recurred non-small cell lung cancer: a multi-institutional retrospective cohort study’
Authors: Chengcheng Zhang, Jingru Qin, Xiaoxue Zhao, Lu Yang, Zhongqi Wang
Journal: International Journal of Surgery (2024)

Zhang, Chengcheng; Qin, Jingru; Zhao, Xiaoxue; Yang, Lu; Wang, Zhongqi Author Information
Recent advances in the treatment of renal stones using flexible ureteroscopys
Authors: Min He, Yonghui Dong, Wansong Cai, Jiale Cai, Yaming Xie, Mingke Yu, Changjiu Li, Liping Wen
Journal: International Journal of Surgery (2024)

Upper urinary tract stones are a common urological disease that can be treated by flexible ureteroscopy (FURS) through the natural urinary tract, in addition to extracorporeal shock wave lithotripsy (ESWL) and percutaneous nephrolithotomy (PCNL). The advantages of FURS are less trauma, faster recovery, and fewer complications, while its disadvantages include poor results of lithotripsy and stone extraction when dealing with larger stones, and prolonged operation time. Over the last two decades, the emergence of new technologies such as FURS combined with negative pressure suction, robot-assisted FURS, and artificially intelligent FURS, coupled with improvements in laser technology (the use of thulium fiber lasers (TFL) and the invention of single-use flexible ureteroscopes (su-fURS) suitable for primary level application, have significantly increased the global adoption of FURS. This surge in usage holds a promising future in clinical application, benefiting a growing number of patients with renal calculi. Accompanied by changes in technical concepts and therapeutic modalities, the scope of indications for FURS is broadening, positioning it as a potential primary choice for urolithiasis treatment in the future. This review outlines the progress in employing flexible ureteroscopy for the treatment of renal calculi in order to generate insights for further research.
A commentary on “The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in the targeted therapy and immunological therapy era: a systematic review and meta-analysis”
Authors: Liyao Chen, Yiqiang Liu, Jierui Yang, Aihua Guo, Gaoyang Zhou
Journal: International Journal of Surgery (2024)

aDepartment of Nephrology,The Second People's Hospital of Jiangyou,Jiangyou,621700,Sichuan,China bSchool of Medical Technology,Xi 'an Medical College,Xi 'an, 710021,Shanxi,China cDepartment of Nephrology,Affiliated Hospital of Shaanxi University of Chinese Medicine,Xianyang 712000,Shaanxi,China dDepartment of Neurosurgery,Second Hospital of the Air Force Medical University (Tangdu Hospital), Xi 'an, 710038,Shaanxi,China Co-authors: Liyao Chen and Yiqiang Liu equally contributed to the article. Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article Published online ■ ■ *Corresponding author. Address: Department of Nephrology,Affiliated Hospital of Shaanxi University of Chinese Medicine,Xianyang 712000,Shaanxi,China. E-mail address: [email protected] (G. Zhou). This is an open access article distributed under the Creative Commons Attribution-ShareAlike License 4.0, which allows others to remix, tweak, and build upon the work, even for commercial purposes, as long as the author is credited and the new creations are licensed under the identical terms. http://creativecommons.org/licenses/by-sa/4.0/
A commentary on ‘A dynamic nomogram for predicting intraoperative brain bulge during decompressive craniectomy in patients with traumatic brain injury: a retrospective study’
Authors: Dongzhou Zhuang, Shousen Wang
Journal: International Journal of Surgery (2024)

aFuzong Clinical Medical College of Fujian Medical University, Department of Neurosurgery, Fuzhou, China bFujian Provincial Clinical Medical Research Center for Minimally Invasive Diagnosis and Treatment of Neurovascular Diseases Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. Published online ■ ■ *Corresponding author. Address: Department of Neurosurgery, Fuzong Clinical Medical College of Fujian Medical University, 156 North West Second Ring Road, Gulou District, Fuzhou 350025, China. Tel: +86-0591-24937080; fax: +86-0591-87640785. E-mail address: [email protected] (S. Wang). This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0/
Association between Glucagon-like Peptide-1 Receptor Agonists and the Risk of Glaucoma in Individuals with Type 2 Diabetes
Authors: Siar Niazi, Filip Gnesin, Anna-Sophie Thein, Jens R. Andreasen, Anna Horwitz, Zaynab A. Mouhammad, Baker N. Jawad, Zia Niazi, Nelsan Pourhadi, Bochra Zareini, Amani Meaidi, Christian Torp-Pedersen, Miriam Kolko
Journal: Ophthalmology (2024)